Collection, synthesis, and interpretation of evidence: A proof-of-concept study in COPD

Statistics in Medicine

Volumn 32, Issue 10, 2013, Pages 1621-1634

  Di Scala, L ^a   Kerman, J ^a   Neuenschwander, B ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Bayesian statistics; Clinical input; Evidence synthesis; Historical controls; Meta analysis

Indexed keywords

PLACEBO; TIOTROPIUM BROMIDE;

ARTICLE; BAYES THEOREM; CALCULATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL DECISION MAKING; DATA ANALYSIS; DATA COLLECTION METHOD; DATA EXTRACTION; DATA SYNTHESIS; DRUG EFFICACY; DRUG RESEARCH; EVIDENCE BASED MEDICINE; FORCED EXPIRATORY VOLUME; HUMAN; MATHEMATICAL COMPUTING; PROBABILITY; STUDY DESIGN; SYSTEMATIC ERROR;

BAYES THEOREM; BIOSTATISTICS; BRONCHODILATOR AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; DECISION MAKING; DRUG DISCOVERY; EVIDENCE-BASED MEDICINE; FORCED EXPIRATORY VOLUME; HUMANS; META-ANALYSIS AS TOPIC; MODELS, STATISTICAL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84876436500     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.5730     Document Type: Article

References (40)

1. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health-care Evaluation. Wiley: Chichester, 2004.
2. Berry S, Carlin B, Lee J, Mueller P. Bayesian Adaptive Methods in Clinical Trials. Chapman & Hall: Boca Raton, 2012.
3. FDA. Challenge and opportunity on the critical path to new medical Technologies. March 2004. http://www.fda.gov/.
4. FDA. Guidance for the use of bayesian statistics in medical device clinical trials. February 2010. http://www.fda.gov/.
5. EMA Doc. Ref. EMA/759784/2010. Reflection paper on the need for active control in therapeutic areas where use of placebo is deemed ethical and one or more established medicines are available. November 2010. http://www.ema.europa.eu/.
6. International Conference on Harmonization. E10: choice of control group and related issues in clinical trials. May 2001. http://www.fda.gov/.
7. Pocock S. The combination of randomized and historical controls in clinical trials. Journal of Chronic Diseases 1976; 29:175-188.
8. Ibrahim JG, Chen MH. Power prior distributions for regression models. Statistical Science 2000; 15:46-60.
9. Chen MH, Ibrahim JG. The relationship between the power prior and hierarchical models. Bayesian Analysis 2006; 1(3):551-574.
10. Neuenschwander B, Branson M, Spiegelhalter DJ. A note on the power prior. Statistics in Medicine 2009; 28:3562-3566.
11. Neuenschwander B, Capkun-Niggli G, Branson M, Spiegelhalter DJ. Summarizing historical information on controls in clinical trials. Clinical Trials 2010; 7:5-18.
12. Hobbs BP, Carlin BP, Mandrekar SJ, Sargent DJ. Hierarchical commensurate and power prior models for adaptive incorporation of historical information in clinical trials. Biometrics 2011; 67(3):1047-1056.
13. World Health Organization. COPD Fact Sheet, N. 315. February 2011. www.who.int/mediacenter/factsheets/fs315/english/.
14. Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. The Lancet 1997; 349(9064):1498-1504.
15. Disse B, Speck GA, Rominger KL, Witek TJ, Hammer R. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Science 1999; 64:457-464.
16. Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Moelken M, Beeh K, Rabe KF, Fabbri LM for the POET-COPD Investigators. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. New England Journal of Medicine 2011; 364:1093-1103.
17. Higgins JPT, Green S (eds). Cochrane handbook for systematic reviews of interventions, version 5.1.0. March 2011. www.cochrane-handbook.org.
18. Littner MR, Ilowite JS, Tashkin DP, Friedman M, Serby CW, Menjoge SS, Witek TJ. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2000; 161:1136-1142.
19. Donohue JF, van Noord JA, Bateman ED, Langley SJ, Lee A, Witek TJ, Kesten SJ, Towse L. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122:47-55.
20. Calverley PMA, Lee A, Towse L, van Noord J, Witek TJ, Kelsen S. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax 2003; 58:855-860.
21. Covelli H, Sudipta Bhattacharya MS, Cassino C, Conoscenti C, Kesten S. Absence of electrocardiographic findings and improved function with once-daily tiotropium in patients with chronic obstructive pulmonary disease. Pharmacotherapy 2005; 25(12):1708-1718.
22. Freeman D, Lee A, Price D. Efficacy and safety of tiotropium in COPD patients in primary care - the SPiRiva Usual CarE (SPRUCE) study. Respiratory Research 2007; 8:45-54.
23. Donohue D, Fogarty C, Loetvall J, Mahler D, Worth H, Yorgancioglu A, Iqbal A, Swales J, Ower R, Higgins M, Kramer B for the INHANCE Study Investigators. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. American Journal of Respiratory and Critical Care Medicine 2010; 182:155-162.
24. Vogelmeier C, Ramos-Barbon D, Jack D, Piggott S, Owen R, Higgins M, Kramer B, INTIME study investigators (INdacaterol & TIotropium: Measuring Efficacy). Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. Respiratory Research 2010; 11:135-142.
25. Verkindre C, Fukuchi Y, Flemale A, Takeda A, Overend T, Prasad N, Dolker M. Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respiratory Medicine 2010; 104:1482-1489.
26. Egger M, Smith GD, Altman DG. Systematic Reviews in Health Care: Meta-analysis in Context. BMJ Books: London, 2001.
27. Hardy RJ, Thompson SG. A likelihood approach to meta-analysis with random effects. Statistics in Medicine 1996; 15(6):619-629.
28. Hartung J, Knapp G, Sinha BK. Statistical Meta-analysis with Applications. Wiley: Chichester, 2008.
29. Higgins JPT, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. Journal of the Royal Statistical Society (Series A) 2009; 172:137-159.
30. Morita S, Thall PF, Muller P. Determining the prior effective sample size of a parametric prior. Biometrics; 64:595-602.
31. Casella G, Berger RL. Reconciling Bayesian and frequentist evidence in the one-sided testing problem. Journal of the American Statistical Association 1987; 82:106-111.
32. Berger J, Sellke T. Testing a point null hypothesis: the irreconcilability of P-values and evidence. Journal of the American Statistical Association 1987; 82:112-139.
33. Neuenschwander B, Rouyrre N, Hollaender N, Zuber E, Branson M. A proof of concept phase II non-inferiority criterion. Statistics in Medicine 2010; 30(13):1618-27.
34. Jones B, Kenwardm MG. Design and Analysis of Cross-over Trials. Chapman & Hall: Boca Raton, 2003.
35. Gelman A. Prior distributions for variance parameters in hierarchical models. Bayesian Analysis 2006; 1(3):515-533.
36. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility. Statistics and Computing 2000; 10:325-337.
37. Evans R, Sedransk J. Combining data from experiments that may be similar. Biometrika 2001; 88(3):643-656.
38. Malec D, Sedransk J. Bayesian methodology for combining the results from different experiments when the specifications for pooling are uncertain. Biometrika 1992; 79(3):593-601.
39. Senn St. Statistical Issues in Drug Development. John Wiley & Sons: Chichester, 2008.
40. O'Hagan A. On outlier rejection phenomena in Bayes inference. Journal of the Royal Statistical Society (Series B) 1979; 41:358-67.